Sint Franciscus Vlietland Groep Stichting

Research site

The Netherlands Vlietlandplein 2, 3118 JH Schiedam, The Netherlands

13 trials recruiting
Hormone receptor positive HER2 negative breast cancer · Renal cell carcinoma · Chronic kidney disease
Adult patients

About Specializations

Sint Franciscus Vlietland Groep Stichting in Schiedam, The Netherlands specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Renal cell carcinoma, Chronic kidney disease, Breast cancer, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Vlietlandplein 23118 JH SchiedamThe Netherlands

Open in maps ↗

Recruiting now: 13 trials
Conditions studied: 28

More sites in Schiedam The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

29 clinical trials

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Mirati Therapeutics Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo

Study on Treatment-Free Intervals for Newly Diagnosed Multiple Myeloma Patients Using Daratumumab, Lenalidomide, and Dexamethasone

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Daratumumab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Prolymphocytic leukaemia+2

Recruiting

Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

Registered drugNo placebo

Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Axitinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Diffuse large B-cell lymphoma

Recruiting

Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

Registered drugNo placebo

Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites